University of Illinois Chicago College of Pharmacy, 833 S Wood St MC 874 161 PHARM, Chicago, IL 60612.
University of Arizona College of Pharmacy Tucson, 1295 N Martin PO Box 210202, Tucson, AZ 85721.
FP Essent. 2021 Sep;508:33-40.
Polypharmacy, defined as concurrent use of five or more drugs, can occur in patients of all ages. Polypharmacy may be appropriate or inappropriate. Appropriate polypharmacy is defined as "use of the correct drugs under appropriate conditions [in order] to treat the right diseases." A prescribed drug becomes inappropriate when its benefits no longer outweigh its risks. Inappropriate polypharmacy has been shown to increase the risks of hospitalization, adverse drug events, clinically relevant drug interactions, and all-cause mortality. Many tools are available to aid physicians in identifying inappropriate polypharmacy. Implicit tools, such as the Medication Appropriateness Index (MAI), provide guidance to be used alongside clinical judgement. Explicit tools, such as the American Geriatrics Society (AGS) Beers Criteria, provide lists of potentially inappropriate drugs and recommend alternatives. Collaboration with pharmacists is important in assessing drug appropriateness. It has been shown to reduce drug-related problems, emergency department visits, and hospitalizations and to improve overall patient health. A patient-centered, team-based approach is recommended in the process of deprescribing inappropriate drugs. Deprescribing should be approached in the same stepwise manner as prescribing of new drugs, and should include patient agreement to changes, evidence-based rationales, and use of dosage tapering strategies.
多药疗法,定义为同时使用五种或更多种药物,可发生在所有年龄段的患者中。多药疗法可能是适当的,也可能是不适当的。适当的多药疗法定义为“在适当的条件下使用正确的药物[以]治疗正确的疾病”。当一种规定的药物的益处不再超过其风险时,它就变得不适当了。不适当的多药疗法已被证明会增加住院、不良药物事件、临床相关药物相互作用和全因死亡率的风险。有许多工具可帮助医生识别不适当的多药疗法。隐含工具,如药物适宜性指数(MAI),提供了与临床判断一起使用的指导。明确的工具,如美国老年医学学会(AGS)的 Beers 标准,提供了潜在不适当药物的清单,并推荐了替代品。与药剂师合作评估药物适宜性非常重要。它已被证明可以减少与药物相关的问题、急诊就诊和住院治疗,并改善整体患者健康。在减少不适当药物的过程中,建议采用以患者为中心、团队为基础的方法。减少不适当药物的方法应与新药物的开具采用相同的逐步方法,并应包括患者对改变的同意、基于证据的理由和使用剂量逐渐减少策略。